爱普列特对良性前列腺增生体外细胞模型的凋亡诱导作用

中国临床药理学与治疗学 ›› 2006, Vol. 11 ›› Issue (6): 644-649.

爱普列特对良性前列腺增生体外细胞模型的凋亡诱导作用

江振洲, 束文慧, 张陆勇, 严明, 孙立, 王广基¹

中国药科大学江苏省新药筛选中心, ¹药物代谢研究中心, 南京 210038, 江苏

收稿日期:2005-12-25 修回日期:2006-05-30 出版日期:2006-06-26 发布日期:2020-12-04
通讯作者: 张陆勇,博士,研究员,博士生导师,研究方向:分子药理学,分子毒理学。Tel:025-83271500 E-mail:lyonzhang@163.com
作者简介:江振洲,硕士研究生,助理研究员,研究方向:分子毒理学。Tel:025-85391056 E-mail:jiangzz@citiz.net
基金资助:
中国药科大学青年教师科技基金项目(NoE0223)

Apoptosis induce effect of epristeride on benign prostatic hyperplasia model cells in vitro

JIANG Zhen-zhou, SHU Wen-hui, ZHANG Lu-yong, YAN Ming, SUN Li, WANG Guang-Ji¹

Jiangsu Center for drugscreening, ¹Center of Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 210038, Jiangsu, China

Received:2005-12-25 Revised:2006-05-30 Online:2006-06-26 Published:2020-12-04

摘要/Abstract

摘要： 目的: 拟建良性前列腺增生体外细胞模型, 并探讨爱普列特(epristeride) 对前列腺增生模型中前列腺细胞作用机制。方法: 建立大鼠前列腺细胞体外培养方法, 给予过量睾酮和多肽生长因子模拟病理环境, 探讨诱发前列腺细胞增生的最佳刺激条件,MTT 实验观察爱普列特对增生前列腺细胞增殖抑制作用, 流式细胞术观察药物对前列腺细胞的凋亡诱导作用。结果: 初步建立了良性前列腺增生体外细胞模型, 培养液(含睾酮9.08×10^-8mol·L^-1) 培养9 d 后, 模型组细胞密度显著增高, 同时培养液中前列腺特异抗原含量提高。爱普列特作用72 h 细胞的IC₅₀值5.0×10^-6mol·L^-1, 流式细胞术分析显示凋亡的特征性亚二倍体峰。结论: 雄激素能显著促进体外培养的大鼠前列腺细胞增殖, 爱普列特可通过诱导前列腺细胞凋亡发挥对前列腺增生疾病的治疗作用。

关键词: 良性前列腺增生, 多肽生长因子, 前列腺特异抗原, 5α-还原酶抑制剂, 流式细胞术

Abstract: AIM: To establish a benign prostatic hyperplasia (BPH) cells model in vitro and investigate the mechanism of epristeride to BPH cells based on this model.Methods: Establishing the primary cultural process of rat prostatic cells.In order to stimulate proliferation of the prostatic cells we simulated the pathophysiological environment and added testrone and polypeptide growth factors (PGFs) into the culture medium.MTT reduction assays were used to observe the inhibition effect of epristeride on BPH model cells in vitro.and the apoptosis induce effect of epristeride was observed by flow cytometry (FMC).Results: In comparison with normal group, the density of BPH model cells was significantly increased by the stimulation effect of testrone (9.08×10^-8mol·L^-1) and PGFs after 9 days;the content of prostate specific antigen in culture medium was increased compared with normal group.The IC₅₀ values of Epriteride to BPH model cells in vitro is 5.0×10^-6mol·L^-1;The cell apoptosis peak was demonstrated by FMC assay.Conclusion: BPH model cells can be establish in vitro by the stimulation of testrone and PGFs;epristeride can induce apoptosis of BPH model cells in vitro and this mechanism is probably the therapeutical effect in clinical use of epristeride.

Key words: benign prostatic hyperplasia, polypeptide growth factors, prostate specific antigen, 5α-reductase inhibitor, flow cytometry

中图分类号:

R965.1

江振洲, 束文慧, 张陆勇, 严明, 孙立, 王广基. 爱普列特对良性前列腺增生体外细胞模型的凋亡诱导作用[J]. 中国临床药理学与治疗学, 2006, 11(6): 644-649.

JIANG Zhen-zhou, SHU Wen-hui, ZHANG Lu-yong, YAN Ming, SUN Li, WANG Guang-Ji. Apoptosis induce effect of epristeride on benign prostatic hyperplasia model cells in vitro[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(6): 644-649.

参考文献

1 Kyprianou N, Jacobs SC, SzostakMJ, Kaur P, Amin P.Apoptosis versus proliferatic activities in human BPH[J].Hum Pathol, 1996;27:668-73
2 Andersen J, Nockel J, Zhao K, Kuperman L, Geimonen E. Epristeride significantly reduce urinariy retention and need for surgeryin patients with symptomatic benign prostatic hyperplasia [J].Urol, 1997;49:839-45
3 Robinson E, Collins A, Dorkin TJ, Marsh C, Neal DE, Leung HY.Effect of a new 5 alpha reductase inhibitor (epristeride) on human prostate cell culture[J].Prostate, 2000;32:259-65
4 Barcher M, Friedrichs B, Kao TC, Cruess DF, Garner D, Foley J, et al.Functional properties of isolated stroma and epithelium from rat ventral prostated uring androgen deprivation and estrogen treatment[J].Exp Clin Endocrinol, 1993;101:69-77
5 Djonov V, Ball R, Vacca A, Ria R, Ribatti D, Semerarof, et al. Effect of epristeride on the expression of IGF-1 and TGF-β receptors in androgen-induced castrated rat prostate[J].Exp Biol Med, 200;226:954-60
6 Coffey DS, Dutta SC, Smith JA Jr, Shappell SB, Chang SS, Cookson MS.Controversies in the management of lower urinary tract symptoms:An overview[J].Brit J Urol, 2002;81:1-5
7 Hayward S, Rosen M,Wang Y, Sudilovsky D, Zhang B, Haughney PC, et al.Stromal-epithelial in the normal and neoplastic prostate[J].Brit J Urol, 2001;79:18
8 Iwamura M, Benning C, Uchida T, Muramoto M, Kyunou H, Egawa S, et al.Over-expression of human epidermal growth factor receptor and cerbB-2 by neuroendocrine cells in normal prostatic tissue[J].Urology, 1998;43:838-43
9 Salvatore M, Franco DS, Raniero I, Chiara M, Stefania L, Paolof, et al.Regional variations of insulin-like growth factor I (IGFI), IGF-II, and receptor type 1 in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens[J].J Clin Endocrinol Metabol, 2001, 86:1700-6
10 Thiel RP, Oesterting JD, Partin AW, Brawer MK, Bartsch G, Horninger W, et al.Multicenter compansion of the diagnostic performance of free prostate specific antigen[J].Urology, 2001; 48:45-9
11 Batislam E, Arik A.Effect of transurethral indwelling catheter on serum prostate specific antigen level in benign prostate hyperplasia[J].Urology, 1999;49:50-4
12 Christensson A, Bjork T, Bruun L, Bjork T, Lilja H, Becker C, et al.Serum prostate specific antigen complexed to alpha 1 antichymotrypsin as an indicator of prostate cancer[J].J Urol, 2003;150:100-5
13 Yamada S, Suzuki M, Takagi A, Murata T, Takahashi H, Ito H, et al.Comparative study on α1-adrenoceptor antagonist binding in human prostate and aorta[J].Clin Exp Pharmacol, 2000;21: 405-9
14 Roger SK, Claus R, Peter B, Georg B, Alain J, Margaret MC, et al.Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the prospective European doxazosin and combination therapy trial[J].Urology, 2003;61:119-26
15 Baine NH, Owings FD, Yu MS.Improved syntheses of epristeride, potent human 5α-reductase inhibitor[J].J Org Chem, 1998;59:5987-9
16 Sun ZY, Wu HY, Wang MY, Tu ZH.The mechanism of epristeride against benign prostate hyperplasia[J].Eur J Pharmacol, 1999;371:227-33

[1]	郑逢佳，贾志君，谢新遥，韩敏，董立厚. 抗体类药物的生物分析方法研究概况[J]. 中国临床药理学与治疗学, 2020, 25(2): 227-232.
[2]	王萍，叶登美，窦德宇，董群. 白芍总苷对EAT小鼠Th1/Th2型细胞因子表达的影响[J]. 中国临床药理学与治疗学, 2016, 21(8): 894-898.
[3]	陈荣生, 罗冬娇, 陈立, 童夏生, 陈豪, 王恩智. 信号传导子及转录激活子-6、前列腺特异抗原在前列腺癌中的表达及意义[J]. 中国临床药理学与治疗学, 2009, 14(9): 1018-1022.
[4]	王荣荣, 江振洲, 习保民, 王涛, 刘晶, 梁忠良, 张陆勇. 苯乙胺类新化合物抗前列腺增生作用研究[J]. 中国临床药理学与治疗学, 2009, 14(7): 726-735.
[5]	韦建瑞, 李彪, 黎庆梅, 郭壮波, 吴沃栋. 西洛他唑与氯吡格雷联合治疗对非ST 段抬高急性冠脉综合征血小板膜糖蛋白的影响[J]. 中国临床药理学与治疗学, 2008, 13(5): 557-562.
[6]	吴玉林, 马秉亮, 祝浩杰, 刘国卿. 洛美利嗪对大鼠脑微血管内皮细胞上 P-糖蛋白活力的影响与 P-gp 及 mdr1 基因 mRNA 表达无关[J]. 中国临床药理学与治疗学, 2006, 11(1): 45-50.
[7]	李玲, 杨素荣, 姚明辉. 新一代胸苷酸合成酶抑制剂ZD1694 的体内外抗肿瘤作用[J]. 中国临床药理学与治疗学, 2005, 10(6): 697-700.
[8]	张法荣. 力至软胶囊治疗良性前列腺增生症的临床研究[J]. 中国临床药理学与治疗学, 2004, 9(12): 1424-1427.
[9]	乔新惠, 唐惠芳, 宋岚, 龙石银, 周弟先, 刘四春. 槲皮素体外逆转白血病细胞耐药性的研究¹[J]. 中国临床药理学与治疗学, 2003, 8(3): 302-303.
[10]	方放治, 戴德哉, 王自正, 王书奎, 翁慎义. 氯苄四氢小檗碱对抗H₂O₂引起无血清培养的血管内皮细胞凋亡及坏死[J]. 中国临床药理学与治疗学, 2002, 7(3): 200-204.